Biogen, Ionis looking for new SMA drugs following Spinraza's success

A freshly inked deal has the biotechs looking at antisense oligonucleotide drug candidates for the treatment of the rare muscular disease.

By Jacob Bell • Dec. 20, 2017

Millendo snaps up Alizé, expanding endocrinology pipeline

Acquiring Alizé will give Millendo a Phase 2 candidate for Prader-Willi syndrome and a foothold in Europe.

By Suzanne Elvidge • Dec. 20, 2017

Hikma to sell Celltrion's Rituxan biosimilar in Africa, Middle East

The London-based generics company already markets in the MENA region two other copycat biologics developed by Celltrion.

By Lisa LaMotta • Dec. 19, 2017

Boehringer Ingelheim inks CNS deal with Autifony

GSK's spinout has hooked up with big pharma Boehringer Ingelheim in a deal to develop a new approach to schizophrenia.

By Suzanne Elvidge • Dec. 19, 2017

Biotech IPOs show no signs of slowing down in 2018

Roughly 40 drugmakers joined U.S. public exchanges in 2017, reflecting a healthy biotech sector, according to market researchers.

By Jacob Bell • Dec. 18, 2017

Biopharma scores big win in tax overhaul

Congress passed a tax code rewrite this week. Here's a cheat sheet for what it means for biopharma.  

By Lisa LaMotta • Dec. 18, 2017

Prescribed Reading: Year-end M&A, Showdown at ASH

New data from the American Society of Hematology conference has the industry buzzing.

By Lisa LaMotta • Dec. 15, 2017

8 Takeout targets to watch in 2018

While dealmaking was sparse in 2017, it's expected to pick up in 2018. Here are eight companies that have good odds of getting acquired.

By Lisa LaMotta • Dec. 15, 2017

Abzena tapped for preclinical ADC development

The CDMO has entered into an agreement worth more than $5 million with a U.S. biotech.

By Jacob Bell • Dec. 14, 2017

Bristol-Myers Squibb picks up I/O programs from Ono

An exclusive deal adds PGE2 receptor antagonists to Bristol-Myers' immuno-oncology portfolio.

By Suzanne Elvidge • Dec. 14, 2017

Vertex licenses its first drug from CRISPR collaboration

CTX001 is a preclinical, ex vivo therapy that the biotechs are looking to push into Phase 1/2 testing for blood disorders in 2018.

By Jacob Bell • Dec. 13, 2017

After a decade of work, Otsuka and GW part ways on Sativex

A fizzled licensing agreement means GW will regain U.S. rights to its cannabinoid drug, which could be more of an albatross than a blessing.

By Jacob Bell • Dec. 13, 2017

Roche snaps up Huntington's drug on positive data

Benefits seen in a Phase 1/2a trial have spurred Roche to pick up its option for Ionis' antisense drug.

By Suzanne Elvidge • Dec. 13, 2017

Allergan picks up Repros to boost women's health offerings

A cheap uterine fibroid drug holds appeal to the specialty pharma. 

By Lisa LaMotta • Dec. 12, 2017

Ardelyx signs a Chinese commercialization deal for GI drug

Fosun is continuing its mission to bring biotech to a Chinese domestic market.

By Suzanne Elvidge • Dec. 12, 2017

Prescribed Reading: Dealmaking begins to pick up as 2018 approaches

It's been a slow year for deals, but it looks like Gilead's buy of Kite could be a catalyst for more M&A. 

By Lisa LaMotta • Dec. 8, 2017

Gilead deepens CAR-T push with deal for Cell Design

Fresh off acquiring Kite Pharma in August, Gilead will acquire Cell Design Labs and its engineering tech for up to $567 million. 

By Ned Pagliarulo • Dec. 7, 2017

Alexion taps Halozyme in platform deal worth $680M

Lured by the potential of Halozyme's drug-delivery technology, Alexion aims to develop subcutaneous formulations for some of its drug candidates. 

By Lisa LaMotta • Dec. 7, 2017

Arena strikes a partnership in Asia

The biotech has found a partner for its two lead drugs – Asia specialist Everest Medicines.

By Suzanne Elvidge • Dec. 5, 2017

J&J jumps in on Actelion spinout's hypertension drug

Through a collaboration deal, Idorsia is handing over rights to aprocitentan in exchange for a $230 million milestone payment.

By Jacob Bell • Dec. 4, 2017

Deal of the Year: Gilead Buys Kite Pharma

Faced with a waning hepatitis C business, Gilead finally came off the M&A sidelines to buy itself a leading position in CAR-T cell therapy. 

By Ned Pagliarulo • Dec. 4, 2017

The BioPharma Dive Awards for 2017

The 2017 BioPharma Dive Awards recognize the industry’s top innovators and disruptors. These executives, companies and trends are transforming the industry and shaping what's to come.

By Ned Pagliarulo , Lisa LaMotta , Jacob Bell • Dec. 4, 2017

Astellas picks up Mitobridge for rare mitochondrial diseases

By exercising its option, Astellas has snagged access to a clinical stage mitochondrial disease therapeutic.

By Suzanne Elvidge • Dec. 4, 2017

CVS Health to buy Aetna in $69B deal

The deal would combine CVS's retail pharmacy services with Aetna's health insurance business, creating a healthcare giant with significant market power.

By Jeff Byers , Shannon Muchmore • Dec. 3, 2017

Prescribed Reading: Industry CEOs talk PRVs, IPR, PCSK9

Leschly suggests PRVs should be an alternative source of revenue for biotechs; ear health R&D is all clogged up; and execs agree the IPR process should be thrown out. 

By Lisa LaMotta • Dec. 1, 2017